Three professors from Tübingen and CeGaT GmbH found CeMeT GmbH for determination, analysis and evaluation of the human metagenome for medical, dental and veterinary issues.
Microbiota summarizes the microorganisms of a particular habitat. It includes useful and harmful bacteria as well as viruses, fungi, and parasites that are found on skin, mucous membranes, or in the human intestine. An ecosystem is formed in which interactions between microorganisms may have both positive and negative effects on human health. The metagenome is the genetic information of the entire microbiota.
The importance of microbiota in the development of chronic diseases is increasingly becoming the focus of research and medicine. “We are convinced that metagenome information will be of high interest for patient care in the near future,” said Professor Ingo Autenrieth, Medical Director of the Institute for Medical Microbiology and Hygiene, University Hospital of Tübingen and one of the founding partners of CeMeT. For example, in recent years many causal correlations have been shown between the microbiota in the intestine and diseases such as inflammatory bowel disease, diabetes, cancer, multiple sclerosis, asthma, and obesity. “The determination and analysis of the metagenome will be increasingly important in medicine to identify risk factors and to plan individual therapies,” adds Isabell Flade, Managing Director of CeMeT. In order to make this a reality, CeGaT has founded the CeMeT GmbH, together with the university professors Ingo Autenrieth, Daniel Huson, and Detlef Weigel, Director at the Tübingen Max-Planck-Institute. Professor Huson, a renowned bioinformatician and Professor Weigel, a leading global evolution and genome researcher, are able to evaluate huge amounts of data obtained in metagenome analysis. CeMeT is the first company that is dedicated solely to the topic of “metagenomics” to solve human medical, dental and veterinary issues. “The expertise we have at CeMeT, including pre-analysis, sequencing, data analysis, microbiology, and medicine is unique in Germany” said Dr. Dirk Biskup, CEO of CeGaT. “This will be of benefit to researchers as well as short- to medium-term to the patient. “It is CeMeT’s mission to determine, analyze and evaluate metagenomes using the latest state of the art technologies. The goal is to clarify medical issues from Tübingen, to lead medical diagnostics of the future.